查看購物車
  • English
  • Japanese
  • Korean
社區型細菌性肺炎市場－全球、區域和國家層面的分析與預測（2025-2035 年）
市場調查報告書
商品編碼
1906304

社區型細菌性肺炎市場－全球、區域和國家層面的分析與預測（2025-2035 年）

Community-Acquired Bacterial Pneumonia Market - A Global and Regional Analysis: Focus on Country and Region - Analysis and Forecast, 2025-2035
出版日期: | 出版商: BIS Research | 英文 90 Pages | 商品交期: 1-5個工作天內

價格

社區型細菌性肺炎（CABP）是由在醫療機構外獲得的細菌引起的肺部感染疾病。

這是最常見的肺炎類型，通常由細菌經由呼吸系統進入肺部引起，導致肺組織發炎和感染。社區型細菌性肺炎最常見的致病菌包括肺炎鏈球菌、流感嗜血桿菌和卡他莫拉菌，但其他細菌也可能引起此病。

社區型細菌性肺炎的常見症狀包括發燒、咳嗽、胸痛、呼吸困難和疲倦。感染的嚴重程度從輕微到嚴重不等，可能需要住院治療，尤其是在老年人、慢性病患者和免疫系統較弱等易感人群中。早期診斷和適當的抗生素治療對於預防呼吸衰竭和敗血症等併發症至關重要。預防措施包括接種疫苗、維持良好的衛生習慣和戒菸。透過適當的醫療管理，社區型細菌性肺炎的預後通常良好，但重症患者和合併基礎疾病的患者可能需要更長的康復時間。

社區型肺炎，尤其是細菌性肺炎，是全球主要的致病和致死原因之一。光是在美國，每年就有約500萬至600萬人患有此病，成人住院率高達20%至30%。根據全球疾病負擔研究，肺炎每年在全球造成超過1億例，其中細菌病原體，特別是肺炎鏈球菌，最常見。如此高且不斷成長的發病率是推動市場發展的主要動力，也促使人們需要更有效的診斷方法、治療方案和預防策略。

全球醫療基礎設施的大量投資在推動社區獲得性細菌性肺炎市場成長方面發揮關鍵作用。各國政府和相關人員不斷擴大醫院設施、提升重症監護能力並改善診斷技術。例如，經合組織成員國預計2022年的平均醫療支出將佔GDP的約9.7%，反映出各國持續重視強化醫療健康體系。印度等新興經濟體預計到2023年公共衛生支出將佔GDP的2.1%，其中相當一部分將用於感染疾病防治和緊急應變。這些基礎設施投資確保了快速診斷、先進的患者管理以及抗生素和疫苗的廣泛應用。這一趨勢不僅改善了患者的治療效果，也推動了對相關治療、診斷和支持性護理解決方案的需求，從而擴大了整體市場。

儘管取得了這些進展，社區型細菌性肺炎市場仍面臨許多挑戰。高成本是阻礙因素。開發新型抗生素和治療方法需要大量的資金投入，包括研發、臨床試驗和監管核准。抗生素，尤其是針對抗藥性菌株的抗生素，需要先進的研發技術和專門的生產流程。與生產、品管和分銷相關的成本進一步加重了這一經濟負擔。這些因素往往限制了市場進入，尤其對於低收入社區和醫保覆蓋不足的患者而言更是如此。此外，製藥公司還面臨著如何在盈利需求和新藥上市的高昂成本之間取得平衡的挑戰，這可能導致創新治療方法的上市延遲和供應有限，最終阻礙社區獲得性細菌性肺炎市場的成長。

社區型細菌性肺炎（CABP）市場細分：

細分 1：按區域

  • 北美洲
  • 歐洲
  • 亞太地區

全球社區型細菌性肺炎市場正經歷重大變革，新的機會正在重塑治療模式並推動市場成長。該市場藥物核准和上市數量的不斷增加，為市場成長帶來了巨大潛力。美國食品藥物管理局(FDA) 和歐洲藥品管理局 (EMA) 等監管機構正在加速核准創新抗生素和治療方法，特別是針對多重抗藥性細菌的療法。隨著全球抗生素抗藥性的持續加劇，對新型高效治療方法的需求日益成長。新藥的核准為製藥公司提供了契機，使其能夠透過推出更有效、更具針對性的治療方法來滿足社區型細菌性肺炎領域尚未滿足的醫療需求。

本報告考察了全球社區獲得性細菌性肺炎市場，並總結了關鍵趨勢、市場影響因素分析、法律制度、市場規模趨勢和預測、按各個細分市場、地區/主要國家進行的詳細分析、競爭格局以及主要企業的概況。

目錄

執行摘要

第1章 全球社區型細菌性肺炎市場：產業分析

  • 市場概覽與生態系統
  • 流行病學分析
  • 主要市場趨勢
    • 影響分析
  • 監管狀態
  • 管道分析
  • 市場動態
    • 概述
    • 市場促進因素
    • 市場限制
    • 市場機遇

2. 全球社區型細菌性肺炎市場（按地區分類）

  • 北美洲
  • 歐洲
  • 亞太地區
    • 市場動態
    • 市場規模及預測
    • 按國家/地區分類的市場規模和預測

第3章：競爭格局與公司概況

  • 競爭格局
    • M&A
    • 夥伴關係、聯盟和業務拓展
    • 新服務
    • 監理活動
    • 資金籌措活動
  • 公司簡介
    • Nabriva Therapeutics.
    • Paratek Pharmaceuticals
    • Eagle Pharmaceutical.
    • Merck & Co.
    • Pfizer Inc.
    • Takeda Pharmaceutical Company Limited. (TiGenix)
    • Melinta Therapeutics LLC.
    • Allergan Plc.
    • Theravance Biopharma Inc.
    • Pfizer, Inc.
    • 其他

第4章調查方法

Product Code: BHL3533SA

Global Community-Acquired Bacterial Pneumonia Market, Analysis and Forecast: 2025-2035

Community-acquired bacterial pneumonia (CABP) is an infection of the lungs caused by bacteria that is contracted outside of a healthcare setting. It is one of the most common types of pneumonia and typically occurs when bacteria enter the lungs through the respiratory tract, leading to inflammation and infection in the lung tissue. The most common pathogens responsible for community-acquired bacterial pneumonia include Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis, though other bacteria can also cause the disease.

Symptoms of community-acquired bacterial pneumonia often include fever, cough, chest pain, difficulty breathing, and fatigue. The infection can range from mild to severe and may require hospitalization, particularly in vulnerable populations such as the elderly, those with chronic conditions, or individuals with compromised immune systems. Early diagnosis and treatment with appropriate antibiotics are crucial to prevent complications such as respiratory failure or sepsis. Prevention strategies include vaccination, good hygiene practices, and smoking cessation. With proper medical management, the prognosis for community-acquired bacterial pneumonia is generally favourable, although recovery may be prolonged in severe cases or for those with underlying health conditions.

Community-acquired pneumonia (CAP), particularly bacterial, is one of the leading causes of morbidity and mortality worldwide. In the U.S. alone, community-acquired pneumonia affects an estimated 5 to 6 million people each year, with hospitalization rates reaching 20-30% among adults. The Global Burden of Disease Study also highlights that pneumonia results in more than 100 million cases globally each year, with bacterial pathogens, particularly Streptococcus pneumoniae, being the most prevalent. This high and growing prevalence acts as a primary driver for the market, necessitating more effective diagnostics, treatment options, and preventive strategies.

Significant investments in healthcare infrastructure worldwide are playing a crucial role in driving the community-acquired bacterial pneumonia market. Governments and private sector stakeholders are continuously enhancing hospital facilities, expanding intensive care capabilities, and improving diagnostic technologies. For instance, OECD countries reported an average healthcare spending of around 9.7% of GDP in 2022, reflecting a sustained focus on strengthening health systems. In emerging economies such as India, public health expenditure rose to 2.1% of GDP in 2023, with major portions allocated to infectious disease control and emergency preparedness. Such infrastructural investments ensure timely diagnosis, advanced patient management, and broader accessibility to antibiotics and vaccines. This trend not only improves patient outcomes but also fuels demand for related therapeutics, diagnostics, and supportive care solutions, thereby expanding the overall market.

Despite these advances, the community-acquired bacterial pneumonia market faces several challenges. The high cost associated with the distribution and development of drugs is a significant constraint within the community-acquired bacterial pneumonia market. The process of developing new antibiotics and therapies requires substantial financial investment in research and development (R&D), clinical trials, and regulatory approvals. This is particularly true for antibiotics targeting resistant bacterial strains, which necessitate advanced research techniques and specialized production processes. The costs associated with manufacturing, quality control, and distribution further exacerbate the financial burden. These factors often result in limited market access, particularly in low-income regions or for patients with inadequate insurance coverage. Additionally, pharmaceutical companies face the challenge of balancing the need for profitability with the substantial costs of bringing a new drug to market, which can result in delays and reduced availability of innovative treatments, ultimately inhibiting the growth of the community-acquired bacterial pneumonia market.

The global community-acquired bacterial pneumonia market is highly competitive, with several leading companies driving innovation and growth, such as Nabriva Therapeutics, Paratek Pharmaceuticals, Eagle Pharmaceutical, Pfizer, Inc., and Merck & Co. Companies in the community-acquired bacterial pneumonia (CABP) market are adopting key strategies to boost growth. One approach is focusing on developing innovative drugs, especially targeting antibiotic-resistant bacteria, to meet unmet medical needs. Firms are also investing heavily in research and development to create more effective and broad-spectrum antibiotics and to improve drug delivery systems. To expand their market presence, companies are forming strategic partnerships and collaborations with research institutions, biotechnology firms, and other pharmaceutical firms to leverage expertise and accelerate product development.

Community-Acquired Bacterial Pneumonia Market Segmentation:

Segmentation 1: by Region

  • North America
  • Europe
  • Asia-Pacific

The global community-acquired bacterial pneumonia market is undergoing significant transformation, fuelled by emerging opportunities that are reshaping treatment paradigms and driving community-acquired bacterial pneumonia market growth. The growing number of drug approvals and launches in the community-acquired bacterial pneumonia market presents a promising opportunity for growth. Regulatory agencies, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), have been fast-tracking approvals for innovative antibiotics and therapies, especially those that target multidrug-resistant bacteria. As antibiotic resistance continues to rise globally, there is an increasing need for new, more effective treatments. The approval of new drugs provides pharmaceutical companies with the opportunity to capitalize on unmet medical needs by introducing more effective and targeted therapies for community-acquired bacterial pneumonia.

Table of Contents

Executive Summary

Scope and Definition

Market/Product Definition

Inclusion and Exclusion

Key Questions Answered

Analysis and Forecast Note

1. Global Community-Acquired Bacterial Pneumonia Market: Industry Analysis

  • 1.1 Market Overview and Ecosystem
  • 1.2 Epidemiological Analysis
  • 1.3 Key Market Trends
    • 1.3.1 Impact Analysis
  • 1.4 Regulatory Landscape
  • 1.5 Pipeline Analysis
  • 1.6 Market Dynamics
    • 1.6.1 Overview
    • 1.6.2 Market Drivers
    • 1.6.3 Market Restraints
    • 1.6.4 Market Opportunities

2. Global Community-Acquired Bacterial Pneumonia Market (by Region), Value ($Million), 2024-2035

  • 2.1 North America
    • 2.1.1 Market Dynamics
    • 2.1.2 Market Sizing and Forecast
    • 2.1.3 North America Community-Acquired Bacterial Pneumonia Market, by Country ($Million), 2024-2035
      • 2.1.3.1 U.S.
  • 2.2 Europe
    • 2.2.1 Market Dynamics
    • 2.2.2 Market Sizing and Forecast
    • 2.2.3 Europe Community-Acquired Bacterial Pneumonia Market, by Country ($Million), 2024-2035
      • 2.2.3.1 U.K.
      • 2.2.3.2 France
      • 2.2.3.3 Germany
      • 2.2.3.4 Italy
      • 2.2.3.5 Spain
  • 2.3 Asia-Pacific
    • 2.3.1 Market Dynamics
    • 2.3.2 Market Sizing and Forecast
    • 2.3.3 Asia-Pacific Community-Acquired Bacterial Pneumonia Market, by Country ($Million), 2024-2035
      • 2.3.3.1 Japan

3. Competitive Landscape and Company Profiles

  • 3.1 Competitive Landscape
    • 3.1.1 Mergers and Acquisitions
    • 3.1.2 Partnership, Alliances and Business Expansion
    • 3.1.3 New Offerings
    • 3.1.4 Regulatory Activities
    • 3.1.5 Funding Activities
  • 3.2 Company Profiles
    • 3.2.1 Nabriva Therapeutics.
      • 3.2.1.1 Overview
      • 3.2.1.2 Top Products / Product Portfolio
      • 3.2.1.3 Top Competitors
      • 3.2.1.4 Target Customers/End-Users
      • 3.2.1.5 Key Personnel
      • 3.2.1.6 Analyst View
    • 3.2.2 Paratek Pharmaceuticals
      • 3.2.2.1 Overview
      • 3.2.2.2 Top Products / Product Portfolio
      • 3.2.2.3 Top Competitors
      • 3.2.2.4 Target Customers/End-Users
      • 3.2.2.5 Key Personnel
      • 3.2.2.6 Analyst View
    • 3.2.3 Eagle Pharmaceutical.
      • 3.2.3.1 Overview
      • 3.2.3.2 Top Products / Product Portfolio
      • 3.2.3.3 Top Competitors
      • 3.2.3.4 Target Customers/End-Users
      • 3.2.3.5 Key Personnel
      • 3.2.3.6 Analyst View
    • 3.2.4 Merck & Co.
      • 3.2.4.1 Overview
      • 3.2.4.2 Top Products / Product Portfolio
      • 3.2.4.3 Top Competitors
      • 3.2.4.4 Target Customers/End-Users
      • 3.2.4.5 Key Personnel
      • 3.2.4.6 Analyst View
    • 3.2.5 Pfizer Inc.
      • 3.2.5.1 Overview
      • 3.2.5.2 Top Products / Product Portfolio
      • 3.2.5.3 Top Competitors
      • 3.2.5.4 Target Customers/End-Users
      • 3.2.5.5 Key Personnel
      • 3.2.5.6 Analyst View
    • 3.2.6 Takeda Pharmaceutical Company Limited. (TiGenix)
      • 3.2.6.1 Overview
      • 3.2.6.2 Top Products / Product Portfolio
      • 3.2.6.3 Top Competitors
      • 3.2.6.4 Target Customers/End-Users
      • 3.2.6.5 Key Personnel
      • 3.2.6.6 Analyst View
    • 3.2.7 Melinta Therapeutics LLC.
      • 3.2.7.1 Overview
      • 3.2.7.2 Top Products / Product Portfolio
      • 3.2.7.3 Top Competitors
      • 3.2.7.4 Target Customers/End-Users
      • 3.2.7.5 Key Personnel
      • 3.2.7.6 Analyst View
    • 3.2.8 Allergan Plc.
      • 3.2.8.1 Overview
      • 3.2.8.2 Top Products / Product Portfolio
      • 3.2.8.3 Top Competitors
      • 3.2.8.4 Target Customers/End-Users
      • 3.2.8.5 Key Personnel
      • 3.2.8.6 Analyst View
    • 3.2.9 Theravance Biopharma Inc.
      • 3.2.9.1 Overview
      • 3.2.9.2 Top Products / Product Portfolio
      • 3.2.9.3 Top Competitors
      • 3.2.9.4 Target Customers/End-Users
      • 3.2.9.5 Key Personnel
      • 3.2.9.6 Analyst View
    • 3.2.10 Pfizer, Inc.
      • 3.2.10.1 Overview
      • 3.2.10.2 Top Products / Product Portfolio
      • 3.2.10.3 Top Competitors
      • 3.2.10.4 Target Customers/End-Users
      • 3.2.10.5 Key Personnel
      • 3.2.10.6 Analyst View
    • 3.2.11 Others

4. Research Methodology

List of Figures

  • Figure: Community-Acquired Bacterial Pneumonia Market (by Scenario), $Million, 2024, 2030, and 2035
  • Figure: Global Community-Acquired Bacterial Pneumonia Market, 2024 and 2035
  • Figure: Global Community-Acquired Bacterial Pneumonia Market Key Trends, Impact Analysis
  • Figure: North America Community-Acquired Bacterial Pneumonia Market, $Million, 2024-2035
  • Figure: Europe Community-Acquired Bacterial Pneumonia Market, $Million, 2024-2035
  • Figure: Asia-Pacific Community-Acquired Bacterial Pneumonia Market, $Million, 2024-2035

List of Tables

  • Table: Market Snapshot
  • Table: Market Dynamics
  • Table: Global Community-Acquired Bacterial Pneumonia Market (by Region), $Million, 2024-2035